CE154344
Project Grant
Overview
Grant Description
Community project funding/Congressionally directed spending - construction - Numerous infectious diseases such as tuberculosis (TB), yellow fever, and influenza have plagued mankind for centuries.
Moreover, increased population density, global warming, and encroachment into new environments continues to accelerate the pace at which new infectious diseases and pandemics emerge.
Unfortunately, marginalized communities have historically been disproportionately affected by the negative health effects induced by widespread or newly emerging diseases.
To further the understanding of many pathogens and to develop safe and effective diagnostics, vaccinations, and treatments against them, the University of Washington (UW) operates a specialized biosafety level-3 / animal biosafety level-3 (BSL-3/ABSL-3) high containment facility that is required to work safely with serious and life-threatening pathogens.
Since its opening in 2013, the facility has played a key role in research that protects the people of our nation.
Reliable operation of the facility is critical for ensuring research safety and compliance with regulatory and funding agency requirements.
This includes ensuring proper airflow and air balancing is maintained for containment of pathogens and protection of personnel and the environment.
The facility is and has always been maintained to the highest standards.
However, after years of intensive work, systems and components are aging and experiencing failures that negatively impact research productivity.
As a result, the facility now requires upgrades and refinements to improve its future performance, reliability, and safe operations.
Two primary tasks will be completed through this design-build construction project:
1) The upgrade of facility infrastructure to enhance the facility’s reliability and robustness including modernizing components of the air supply and exhaust systems and partitioning the facility air handling and corridor systems so that the facility can be operated as two independent units and
2) The replacement of two primary containment devices.
After construction is complete, the facility will be fully recommissioned and certified for proper operation by an independent third-party organization.
Through completion of these tasks, the performance, reliability, and safety of the facility will be markedly improved, thereby allowing the continuation and expansion of the critical research activities that spur advances in the diagnosis, treatment, and prevention of life-threatening infectious diseases.
Moreover, increased population density, global warming, and encroachment into new environments continues to accelerate the pace at which new infectious diseases and pandemics emerge.
Unfortunately, marginalized communities have historically been disproportionately affected by the negative health effects induced by widespread or newly emerging diseases.
To further the understanding of many pathogens and to develop safe and effective diagnostics, vaccinations, and treatments against them, the University of Washington (UW) operates a specialized biosafety level-3 / animal biosafety level-3 (BSL-3/ABSL-3) high containment facility that is required to work safely with serious and life-threatening pathogens.
Since its opening in 2013, the facility has played a key role in research that protects the people of our nation.
Reliable operation of the facility is critical for ensuring research safety and compliance with regulatory and funding agency requirements.
This includes ensuring proper airflow and air balancing is maintained for containment of pathogens and protection of personnel and the environment.
The facility is and has always been maintained to the highest standards.
However, after years of intensive work, systems and components are aging and experiencing failures that negatively impact research productivity.
As a result, the facility now requires upgrades and refinements to improve its future performance, reliability, and safe operations.
Two primary tasks will be completed through this design-build construction project:
1) The upgrade of facility infrastructure to enhance the facility’s reliability and robustness including modernizing components of the air supply and exhaust systems and partitioning the facility air handling and corridor systems so that the facility can be operated as two independent units and
2) The replacement of two primary containment devices.
After construction is complete, the facility will be fully recommissioned and certified for proper operation by an independent third-party organization.
Through completion of these tasks, the performance, reliability, and safety of the facility will be markedly improved, thereby allowing the continuation and expansion of the critical research activities that spur advances in the diagnosis, treatment, and prevention of life-threatening infectious diseases.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Washington
United States
Geographic Scope
State-Wide
Related Opportunity
HRSA-24-110
University Of Washington was awarded
Enhancing Biosafety Level-3 Facility for Infectious Disease Research
Project Grant CE154344
worth $3,500,000
from the HRSA Office of Federal Assistance Management in September 2024 with work to be completed primarily in Washington United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.493 Congressional Directives.
Status
(Ongoing)
Last Modified 12/5/24
Period of Performance
9/30/24
Start Date
9/29/27
End Date
Funding Split
$3.5M
Federal Obligation
$0.0
Non-Federal Obligation
$3.5M
Total Obligated
Activity Timeline
Transaction History
Modifications to CE154344
Additional Detail
Award ID FAIN
CE154344
SAI Number
CE154344-624257991
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Other
Awarding Office
75RJ00 HRSA OFFICE OF FEDERAL ASSISTANCE MANAGEMENT
Funding Office
75RR00 HRSA HEALTHCARE SYSTEMS BUREAU
Awardee UEI
HD1WMN6945W6
Awardee CAGE
1HEX5
Performance District
WA-90
Senators
Maria Cantwell
Patty Murray
Patty Murray
Modified: 12/5/24